ADC Therapeutics マネジメント
マネジメント 基準チェック /24
ADC Therapeuticsの CEO はAmeet Mallikで、 May2022年に任命され、 の在任期間は 4.33年です。 の年間総報酬は$ 2.45Mで、 31.6%給与と68.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.66%を直接所有しており、その価値は$ 2.76M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と5.3年です。
主要情報
Ameet Mallik
最高経営責任者
US$2.5m
報酬総額
| CEO給与比率 | 31.64% |
| CEO在任期間 | 4.3yrs |
| CEOの所有権 | 1.7% |
| 経営陣の平均在職期間 | 3.8yrs |
| 取締役会の平均在任期間 | 5.3yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Aug 14
ADCT: LOTIS-5 Reset And LOTIS-7 Optionality Will Support Future Upside
Analysts have cut their average price targets for ADC Therapeutics, moving closer to the recent reductions to $5 and $2. They cite what they describe as underwhelming LOTIS-5 data, a tougher perceived benefit risk profile for Zynlonta, and higher regulatory uncertainty.ナラティブ更新 • Jun 26
ADCT: Reset Expectations On LOTIS-5 Will Support Future Upside Potential
Analysts have reduced their average price target on ADC Therapeutics from about $7.50 to roughly $5.00, reflecting concerns about Zynlonta's risk-benefit profile, modest LOTIS-5 trial outcomes, and increased regulatory risk highlighted in recent research updates. Analyst Commentary Recent research on ADC Therapeutics centers on how the LOTIS-5 trial reshapes expectations for Zynlonta, regulatory risk, and the company’s potential to create value through its broader pipeline.
ナラティブ更新 • Jun 11
ADCT: Future Earnings Potential Will Rely On Managing LOTIS-5 Safety Risks
Narrative Update: ADC Therapeutics Analyst Price Target Reset Analysts have cut their average price target for ADC Therapeutics to $2, from prior estimates closer to $6. This reflects concerns about Zynlonta's risk benefit profile and added regulatory risk following the LOTIS-5 trial results.Seeking Alpha • Jun 06
ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy
Summary ADC Therapeutics is downgraded from 'Strong Buy' to 'Sell' due to safety concerns in ZYNLONTA's phase 3 LOTIS-5 trial. While ZYNLONTA + rituximab met the primary PFS endpoint, the regimen showed higher serious adverse events and Grade 5 TEAEs versus the comparator. Lack of overall survival benefit and increased withdrawals further undermine the risk-benefit profile for 2nd-line r/r DLBCL expansion. Strategic alternatives, including cost reductions, are under consideration, as regulatory and commercial prospects for ZYNLONTA become uncertain. Read the full article on Seeking Alphaナラティブ更新 • May 28
ADCT: Higher Revenue And Margin Assumptions Will Support Future Earnings Potential
Analysts have raised their price target for ADC Therapeutics by $1, citing updated assumptions around revenue growth, profit margins, and future P/E expectations as key drivers of the revision. Analyst Commentary While the latest price target revision for ADC Therapeutics reflects updated assumptions on revenue, margins, and P/E, bearish analysts continue to flag several risks that could limit upside if execution falls short.分析記事 • May 07
Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report
It's been a good week for ADC Therapeutics SA ( NYSE:ADCT ) shareholders, because the company has just released its...ナラティブ更新 • May 03
ADCT: Updated Capital Plans And Refined Assumptions Will Support Future Upside Potential
Analysts have increased their price target on ADC Therapeutics by $1, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that they believe better align the valuation with current fundamentals and expectations. Analyst Commentary Despite the modest $1 lift in the price target, recent commentary around ADC Therapeutics still carries a cautious tone.ナラティブ更新 • Apr 19
ADCT: Refined Risk And Earnings Assumptions Will Support Future Upside Potential
Analysts raised their price target on ADC Therapeutics by $1, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that collectively fine tune their outlook rather than overhaul it. Analyst Commentary Bearish analysts are treating the latest US$1 price target adjustment as a refinement rather than a signal of strong conviction, and their commentary leans cautious around execution, valuation and growth visibility.ナラティブ更新 • Apr 05
ADCT: Refreshed Revenue And Margin Assumptions Will Strengthen Future Earnings Power
Analysts have lifted their price target on ADC Therapeutics by $1, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the change. Analyst Commentary While the latest price target adjustment reflects refreshed modeling on discount rates, revenue assumptions, margins and future P/E, bearish analysts are still flagging several areas of concern that they see as reasons to stay cautious.ナラティブ更新 • Mar 21
ADCT: Higher Revenue Assumptions Will Support Stronger Future Earnings Power
Analysts have lifted their price target fair value for ADC Therapeutics from $5.00 to $6.00, citing updated assumptions for revenue growth, profit margins and future P/E that change their overall assessment of risk and return. Valuation Changes Fair Value: raised from $5.00 to $6.00 per share, indicating a higher assessed intrinsic value.ナラティブ更新 • Mar 04
ADCT: Higher Revenue Outlook And Richer P/E Multiple Will Support Upside
Analysts have trimmed their price target on ADC Therapeutics to $7.50 from $8.20, citing updated assumptions that combine higher projected revenue growth with lower expected profit margins and a higher future P/E multiple. Valuation Changes Fair Value: reduced from $8.20 to $7.50, a modest cut to the target level used in the model.分析記事 • Feb 05
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking
ADC Therapeutics SA's ( NYSE:ADCT ) price-to-sales (or "P/S") ratio of 6.7x might make it look like a buy right now...分析記事 • Sep 30
ADC Therapeutics SA (NYSE:ADCT) Held Back By Insufficient Growth Even After Shares Climb 31%
Despite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 31% in...分析記事 • May 27
Shareholders Will Likely Find ADC Therapeutics SA's (NYSE:ADCT) CEO Compensation Acceptable
Key Insights ADC Therapeutics to hold its Annual General Meeting on 3rd of June CEO Ameet Mallik's total compensation...分析記事 • May 17
Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results
ADC Therapeutics SA ( NYSE:ADCT ) just released its first-quarter report and things are looking bullish. Results...分析記事 • Apr 04
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 31% in the last thirty...
新しいナラティブ • Apr 03
Expanding ZYNLONTA Trials Will Broaden DLBCL Treatment Options
Expanding ZYNLONTA into earlier lines of DLBCL through trials could significantly boost revenue by accessing a larger patient population.Seeking Alpha • Mar 25
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
Summary ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion. Despite a challenging competitive landscape, ADCT's current valuation and cash position make it a high-risk/high-reward investment, meriting a "Buy" sentiment with caution. Read the full article on Seeking Alpha分析記事 • Mar 10
Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying?
Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$1.47 ADC...分析記事 • Feb 12
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Unfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 26% in the last thirty...Seeking Alpha • Dec 12
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL
Summary Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034. Antibody-drug conjugate with monoclonal antibody directed CD-22 ADCT-602 is being explored in a phase 1/2 study for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Read the full article on Seeking Alpha分析記事 • Nov 16
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
ADC Therapeutics SA ( NYSE:ADCT ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Jul 18
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Those holding ADC Therapeutics SA ( NYSE:ADCT ) shares would be relieved that the share price has rebounded 34% in the...Seeking Alpha • Jun 06
Limiting Concerns On ADC Therapeutics' Prospects
Summary ADC Therapeutics is developing antibody-drug conjugates for hematologic cancers and solid tumors. Their drug Zynlonta shows promise in targeting and killing cancer cells while reducing damage to healthy tissues. ADCT's pipeline includes ADCT-601 and ADCT-602 for solid tumors and acute lymphoblastic leukemia. ADCT has significant cash burn and debt, leading to financial constraints and a limited cash runway. Despite a promising pipeline, ADCT's high valuation and competitive challenges justify a "hold" rating. Read the full article on Seeking Alpha分析記事 • May 30
ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
The ADC Therapeutics SA ( NYSE:ADCT ) share price has fared very poorly over the last month, falling by a substantial...分析記事 • May 10
Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
ADC Therapeutics SA ( NYSE:ADCT ) shareholders are probably feeling a little disappointed, since its shares fell 3.4...Seeking Alpha • Mar 19
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Summary ADC Therapeutics has experienced a 200%+ recovery since being undervalued and trading below their cash on hand. The company's prospects are now uncertain as they face challenges in getting a foothold for their approved antibody-drug conjugate. The success of the phase 3 trial for loncastuximab will determine the company's near-term aspirations and market sentiment. Read the full article on Seeking Alpha分析記事 • Mar 17
ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
ADC Therapeutics SA ( NYSE:ADCT ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...分析記事 • Jan 18
ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Despite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 38% in...Seeking Alpha • Dec 29
ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Summary ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted trial for second line treatment was a setback. New data shows that the combination of Zynlonta and Rituximab can cure certain types of lymphoma, and ADCT has a robust pipeline of potential therapies. Read the full article on Seeking Alpha分析記事 • Dec 14
An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$2.71 Current share...Seeking Alpha • Dec 01
ADC Therapeutics: Navigating A Swirling Drain
Summary ADC Therapeutics (ADCT) is trading well below its cash on hand, underlying its severely poor sentiment from investors. ADCT's main molecule, loncastuximab tesirine, has shown positive results in the relapse/refractory setting. ADCT has other pipeline projects in development, with data from phase 1 studies expected in the first half of 2024. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$97m |
| Mar 31 2026 | n/a | n/a | -US$137m |
| Dec 31 2025 | US$2m | US$776k | -US$143m |
| Sep 30 2025 | n/a | n/a | -US$167m |
| Jun 30 2025 | n/a | n/a | -US$170m |
| Mar 31 2025 | n/a | n/a | -US$150m |
| Dec 31 2024 | US$2m | US$746k | -US$158m |
| Sep 30 2024 | n/a | n/a | -US$212m |
| Jun 30 2024 | n/a | n/a | -US$215m |
| Mar 31 2024 | n/a | n/a | -US$227m |
| Dec 31 2023 | US$4m | US$721k | -US$240m |
| Sep 30 2023 | n/a | n/a | -US$181m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$200m |
| Dec 31 2022 | US$11m | US$475k | -US$157m |
報酬と市場: Ameetの 総報酬 ($USD 2.45M ) は、 US市場 ($USD 1.60M ) の同規模の企業の平均を上回っています。
報酬と収益: Ameetの報酬は増加しましたが、会社は利益を上げていません。
CEO
Ameet Mallik (53 yo)
4.3yrs
在職期間
US$2,453,150
報酬
Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He had been a Director of Atara Biotherapeutics, Inc. since August 2021 until September 2025. Dr. Mallik serves as Chief...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | US$2.45m | 1.66% $ 2.8m | |
| Chief Financial Officer | 3.8yrs | US$1.25m | 0.24% $ 393.6k | |
| Chief Medical Officer | 3.7yrs | US$1.52m | 0.19% $ 317.0k | |
| Corporate Controller & Chief Accounting Officer | no data | データなし | 0.029% $ 48.6k | |
| Chief Technical Officer | 2.7yrs | データなし | データなし | |
| Head of Investor Relations & Corporate Communications | no data | データなし | データなし | |
| Secretary and Chief Legal & Compliance Officer | 3.8yrs | データなし | 0.14% $ 232.8k | |
| Senior VP & Chief People Officer | 6.1yrs | データなし | データなし | |
| Chief Commercial Officer | 3.8yrs | データなし | データなし | |
| Investor Relations Officer | no data | データなし | データなし |
3.8yrs
平均在職期間
56.5yo
平均年齢
経験豊富な経営陣: ADCTの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | US$2.45m | 1.66% $ 2.8m | |
| Vice-Chairman & Lead Independent Director | 7.3yrs | US$250.97k | 0.17% $ 283.9k | |
| Independent Non-Executive Director | 1.3yrs | US$431.13k | 0.021% $ 35.6k | |
| Chairman of the Board | 6.4yrs | US$249.20k | 0.061% $ 102.0k | |
| Independent Non-Executive Director | 4.3yrs | US$206.10k | 0.074% $ 122.6k | |
| Independent Non-Executive Director | 8.3yrs | データなし | データなし | |
| Independent Non-Executive Director | 6.4yrs | US$211.10k | 0.075% $ 124.4k | |
| Independent Director | 3.3yrs | US$211.10k | 0.053% $ 88.1k | |
| Independent Non-Executive Director | 5.3yrs | US$246.41k | 0.11% $ 183.9k |
5.3yrs
平均在職期間
59yo
平均年齢
経験豊富なボード: ADCTの 取締役会 は 経験豊富 であると考えられます ( 5.3年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/09 13:20 |
| 終値 | 2026/09/09 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ADC Therapeutics SA 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21
| アナリスト | 機関 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Naureen Quibria | Capital One Securities, Inc. |